Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.49 |
| ▸ | CCR8 | P51685 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28251402 | 0.84 | CYP2C9 (0.44) | KDM4EKMT2AMEN1POLB | |
| SCHEMBL19428062 | 0.83 | KMT2A (0.42) | KDM4EPKMKMT2ACCR8MEN1 | |
| SCHEMBL1651945 | 0.82 | KMT2A (0.80) | KDM4EPKMKMT2AGPR119CCR8 | |
| SCHEMBL10102249 | 0.77 | KDM4E (0.62) | KDM4EPKMKMT2AGPR119CCR8 | |
| SCHEMBL13199301 | 0.77 | KDM4E (0.68) | KDM4EPKMKMT2AGPR119CCR8 | |
| SCHEMBL19410867 | 0.76 | HPGD (0.50) | KDM4EPKMGPR119STSPTPN2 | |
| SCHEMBL20583811 | 0.74 | KDM4E (0.55) | KDM4EPKMKMT2AGPR119CCR8 | |
| SCHEMBL14450278 | 0.74 | KDM4E (0.64) | KDM4EPKMKMT2AGPR119CCR8 | |
| SCHEMBL26131403 | 0.74 | KDM4E (1.00) | KDM4EPKMKMT2AGPR119CCR8 | |
| SCHEMBL18860240 | 0.73 | KDM4E (0.57) | KDM4EPKMKMT2AGPR119CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11026936-B2 | Piperidinyl-propanone derivatives | MERCK PATENT GMBH (DE) | 2021-06-08 | — | — | US | disclosed |
| US-20200253949-A1 | PIPERIDINYL-PROPANONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-08-13 | — | — | US | disclosed |
| EP-3436443-B1 | N1-(3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE | MERCK PATENT GMBH (DE) | 2020-03-11 | — | — | EP | disclosed |
| EP-3436443-A1 | N1-(3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE | Merck Patent GmbH (DE) | 2019-02-06 | — | — | EP | disclosed |
| WO-2017167676-A1 | N1-(3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE | MERCK PATENT GMBH (DE) | 2017-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11026936-B2 | Piperidinyl-propanone derivatives | PDK2, PDK3, PDK1 | KDM4E 1276/4885PKM 14/4885KMT2A 1910/4885 |
| US-20200253949-A1 | PIPERIDINYL-PROPANONE DERIVATIVES | PDK2, PDK3, PDK1 | KDM4E 1276/4885PKM 14/4885KMT2A 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.